Yesterday, Dec. 30, 2015, 53 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $34.22 to $7,500,000.00.

Highlighted Stocks Traded by Insiders:

Eleven Biotherapeutics (EBIO) - FREE Research Report

Tubridy Karen L, who is Chief Development Officer at Eleven Biotherapeutics, sold 4,427 shares at $2.85 on Dec. 30, 2015. Following this transaction, the Chief Development Officer owned 32,973 shares meaning that the stake was reduced by 11.84% with the 4,427-share transaction.

Furfine Eric Steven, who is Chief Scientific Officer at Eleven Biotherapeutics, sold 4,652 shares at $2.85 on Dec. 30, 2015. Following this transaction, the Chief Scientific Officer owned 34,648 shares meaning that the stake was reduced by 11.84% with the 4,652-share transaction.

Celniker Abbie, who is President and CEO at Eleven Biotherapeutics, sold 10,155 shares at $2.85 on Dec. 30, 2015. Following this transaction, the President and CEO owned 429,975 shares meaning that the stake was reduced by 2.31% with the 10,155-share transaction.

The shares most recently traded at $2.90, up $0.05, or 1.72% since the insider transaction. Historical insider transactions for Eleven Biotherapeutics go as follows:

  • 4-Week # shares sold: 33,400
  • 12-Week # shares sold: 33,400
  • 24-Week # shares sold: 33,400

The average volume for Eleven Biotherapeutics has been 75,500 shares per day over the past 30 days. Eleven Biotherapeutics has a market cap of $57.0 million and is part of the health care sector and drugs industry. Shares are down 75.42% year-to-date as of the close of trading on Wednesday.

Eleven Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of protein therapeutics to treat eye diseases primarily in the United States. The company develops its therapeutics through AMP-Rx, a proprietary protein engineering platform. Currently, there are 2 analysts who rate Eleven Biotherapeutics a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on EBIO - FREE

TheStreet Quant Ratings

rates Eleven Biotherapeutics as a

sell

. The company's weaknesses can be seen in multiple areas, such as its disappointing return on equity and generally disappointing historical performance in the stock itself. Get the full

Eleven Biotherapeutics Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Chimerix (CMRX) - FREE Research Report

Mario Ernest, who is Director at Chimerix, bought 125,000 shares at $7.09 on Dec. 30, 2015. Following this transaction, the Director owned 262,637 shares meaning that the stake was boosted by 90.82% with the 125,000-share transaction.

Machado Clarence Patrick, who is Director at Chimerix, bought 10,000 shares at $7.08 on Dec. 30, 2015. Following this transaction, the Director owned 10,000 shares meaning that the stake was boosted by 100% with the 10,000-share transaction.

The shares most recently traded at $8.99, up $1.91, or 21.19% since the insider transaction. Historical insider transactions for Chimerix go as follows:

  • 4-Week # shares bought: 1,950
  • 4-Week # shares sold: 122,950
  • 12-Week # shares bought: 1,950
  • 12-Week # shares sold: 122,950
  • 24-Week # shares bought: 1,950

TheStreet Recommends

  • 24-Week # shares sold: 122,950

The average volume for Chimerix has been 1.0 million shares per day over the past 30 days. Chimerix has a market cap of $340.1 million and is part of the health care sector and drugs industry. Shares are down 79.31% year-to-date as of the close of trading on Wednesday.

Chimerix, Inc., a biopharmaceutical company, discovers, develops, and commercializes oral antivirals to address unmet medical needs in the United States. Currently, there are 2 analysts who rate Chimerix a buy, no analysts rate it a sell, and 8 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on CMRX - FREE

TheStreet Quant Ratings

rates Chimerix as a

sell

. The company's weaknesses can be seen in multiple areas, such as its feeble growth in its earnings per share, deteriorating net income, disappointing return on equity, weak operating cash flow and generally disappointing historical performance in the stock itself. Get the full

Chimerix Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Handy & Harman (HNH) - FREE Research Report

Frankfurt Robert, who is Director at Handy & Harman, bought 3,488 shares at $20.52 on Dec. 30, 2015. Following this transaction, the Director owned 20,221 shares meaning that the stake was boosted by 20.85% with the 3,488-share transaction.

The shares most recently traded at $20.44, down $0.08, or 0.39% since the insider transaction. Historical insider transactions for Handy & Harman go as follows:

  • 4-Week # shares bought: 4,000
  • 12-Week # shares bought: 4,000
  • 24-Week # shares bought: 4,000

The average volume for Handy & Harman has been 18,400 shares per day over the past 30 days. Handy & Harman has a market cap of $250.0 million and is part of the industrial goods sector and industrial industry. Shares are down 55.53% year-to-date as of the close of trading on Tuesday.

Handy & Harman Ltd. manufactures and sells engineered niche industrial products in the United States and internationally. It operates through Joining Materials, Tubing, Building Materials, and Kasco Blades and Route Repair Services segments. The company has a P/E ratio of 14.4.

Exclusive Offer: Get the latest Stock Analysis on HNH - FREE

TheStreet Quant Ratings

rates Handy & Harman as a

hold

. The company's strengths can be seen in multiple areas, such as its revenue growth, good cash flow from operations and largely solid financial position with reasonable debt levels by most measures. However, as a counter to these strengths, we also find weaknesses including feeble growth in the company's earnings per share, disappointing return on equity and poor profit margins. Get the full

Handy & Harman Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.